PMID- 18807213
OWN - NLM
STAT- MEDLINE
DCOM- 20090820
LR  - 20181113
IS  - 1219-4956 (Print)
IS  - 1219-4956 (Linking)
VI  - 15
IP  - 2
DP  - 2009 Jun
TI  - The efficient generation of immunocompetent dendritic cells from leukemic blasts 
      in acute myeloid leukemia: a local experience.
PG  - 257-67
LID - 10.1007/s12253-008-9105-1 [doi]
AB  - Dendritic cells (DCs) are the most important antigen presenting cells with 
      potentially useful applications in cancer immunotherapy. Leukemic cells of 
      patients with acute myeloid leukemia (AML) could be differentiated to DC-like 
      cells possessing the ability of stimulating anti-leukemic immune response. 
      Despite obvious progress in DC-based immunotherapy, some discrepancies were 
      reported in differentiation potential of AML blasts from all patients toward DC 
      like cells. The present study, as a local experience, was set up to generate DCs 
      from AML blasts of various subtypes. Leukemic Blasts from 16 Iranian AML patients 
      were differentiated into functional DCs by culturing in the presence of rhGM-CSF, 
      rhIL-4 and TNF-alpha for 8 days. The morphology, expression of key surface 
      molecules and allostimulatory activity of resultant DCs were compared with 
      primary blasts and cultured but cytokine untreated control groups. The pattern of 
      angiotensin-converting enzyme (ACE) expression was used to approve the leukemic 
      origin of generated DCs. Neo-expression or upregulation of DC-associated markers 
      were occurred during culturing period in cytokine treated cells compared with 
      primary blasts and cultured but cytokine untreated control groups: CD1a (63.22% 
      vs. 3.22% and 11.79%), CD83 (41.27% vs. 0.11% and 0.70%), CD40 (15.17% vs. 0.00% 
      and 0.04%), CD80 (49.96 vs. 0.02% and 0.32%), CD86 (56.49% vs. 0.50% and 5.71%) 
      and HLA-DR (52.52% vs. 14.32% and 2.49%) respectively. The potency of generated 
      DCs to induce allogeneic T cell proliferation increased significantly compared to 
      pre and post culture control groups (27,533.4 +/- 2,548.3, 8,820.4 +/- 1,639.4 
      and 3,200.35 +/- 976 respectively). The expression pattern of ACE in AML-DCs, 
      blast cells and DCs derived from normal monocytes (7.93%, 1.28% and 74.97% 
      respectively) confirmed the leukemic origin of DCs. Our data confirmed the 
      generation of sufficient AML-derived cells with the properties of DCs in all 
      cases. This potency of AML blasts, offers a useful route for active immunotherapy 
      of AML patients.
FAU - Bagheri, Kambiz
AU  - Bagheri K
AD  - Department of Immunology, Faculty of Medical Sciences, Tarbiat Modares 
      University, P.O. Box 14115-331, Tehran, Iran.
FAU - Alimoghadam, Kamran
AU  - Alimoghadam K
FAU - Pourfathollah, Ali Akbar
AU  - Pourfathollah AA
FAU - Hassan, Zuhair Muhammad
AU  - Hassan ZM
FAU - Hajati, Jamshid
AU  - Hajati J
FAU - Moazzeni, Seyyed Mohammad
AU  - Moazzeni SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20080920
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
RN  - EC 3.4.15.1 (Peptidyl-Dipeptidase A)
SB  - IM
MH  - Adult
MH  - Antigen-Presenting Cells
MH  - Cell Differentiation
MH  - Cell Proliferation
MH  - Child
MH  - Child, Preschool
MH  - Dendritic Cells/*immunology
MH  - Female
MH  - Flow Cytometry
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - Humans
MH  - Immunophenotyping
MH  - Interleukin-4/pharmacology
MH  - Leukemia, Myeloid, Acute/*pathology
MH  - Lymphocyte Activation
MH  - Male
MH  - Middle Aged
MH  - Peptidyl-Dipeptidase A/metabolism
MH  - Recombinant Proteins/pharmacology
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor-alpha/pharmacology
MH  - Young Adult
EDAT- 2008/09/23 09:00
MHDA- 2009/08/21 09:00
CRDT- 2008/09/23 09:00
PHST- 2008/07/06 00:00 [received]
PHST- 2008/09/02 00:00 [accepted]
PHST- 2008/09/23 09:00 [pubmed]
PHST- 2009/08/21 09:00 [medline]
PHST- 2008/09/23 09:00 [entrez]
AID - 10.1007/s12253-008-9105-1 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2009 Jun;15(2):257-67. doi: 10.1007/s12253-008-9105-1. Epub 
      2008 Sep 20.